Aardvark Therapeutics: $85 Million Raised To Develop Therapeutics For Activating Innate Homeostatic Pathways To Treat Metabolic Diseases
By Amit Chowdhry ● May 18, 2024
Aardvark Therapeutics has raised an $85 million oversubscribed Series C financing led by Decheng Capital, with participation from Cormorant Asset Management, Surveyor Capital, SymBiosis, Tetragon Financial Group, Walleye Capital, Laurion Capital Management, LG Technology Ventures, Cantor Ventures, Silver Arc Private Capital, The Prader-Willi Syndrome Association – USA, and existing investors, including Vickers Venture Partners and the Foundation for Prader-Willi Research. Decheng Capital's Managing Director, Victor Tong, Jr., joined Aardvark's board of Directors in connection with the investment.